IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
In light of the emerging data from the company's ongoing randomized clinical trial of aplitabart in second-line metastatic colorectal cancer, together with the significant opportunity in autoimmunity, the company has decided to reduce workforce and minimize its future spending on the research and clinical development of aplitabart and other oncology candidates.On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases.
IGm生物科学公司（纳斯达克: IGMS）周二宣布战略转变和管道转型，加快并深化其在开发针对自身免疫性疾病的t细胞结合Igm抗体方面的领导地位。
The company's lead candidates include imvotamab, which is being developed for rheumatoid arthritis, systemic lupus erythematosus, and myositis, and IGM-2644, which is expected to enter a clinical study for generalized myasthenia gravis by the end of 2024.
公司的主要候选药品包括imvotamab，该药正在开发用于类风湿性关节炎、系统性红斑狼疮和肌炎，以及IGm-2644，预计将于2024年年底进入用于全身性重症肌无力的临床研究。
IGM to minimize future spending on aplitabart and other oncology candidates.
IGm将尽量减少未来在aplitabart和其他肿瘤候选药品上的支出。
In light of the emerging data from the company's ongoing randomized clinical trial of aplitabart in second-line metastatic colorectal cancer, together with the significant opportunity in autoimmunity, the company has decided to reduce workforce and minimize its future spending on the research and clinical development of aplitabart and other oncology candidates.
鉴于公司正在进行的关于aplitabart在次线转移性结直肠癌治疗中的随机临床试验的新数据，以及在自身免疫疾病领域的重大机遇，公司决定减少员工数量并最小化未来在aplitabart和其他肿瘤候选药品的研究和临床开发支出。
The company expected to release aplitabart top-line progression-free survival results from randomized colorectal cancer trial by the end of the first quarter of 2025.
公司预计将于2025年第一季度末发布有关aplitabart在随机结直肠癌试验中的顶级无进展生存结果。
As a result of these actions, IGM believes it can extend its current cash runway into 2027.
由于这些举措，igm相信可以将目前的现金储备延长至2027年。
As part of the company's strategic pivot to autoimmunity, Fred Schwarzer, CEO, President, and Director, and Bruce Keyt, chief scientific officer, will step down from their current roles.
作为公司战略转向自身免疫性的一部分，CEO、总裁和董事Fred Schwarzer以及首席科学官Bruce Keyt将从各自的现任职务中辞职。
IGM has appointed ex-Bristol Myers Squibb & Co's executive (NYSE:BMY) Mary Beth Harler as the CEO.
IGm已任命前百时美施贵宝（纽交所: BMY）执行高级副总裁Mary Beth Harler为CEO。
Chris Takimoto, Chief Medical Officer, has also announced to step down.
首席医疗官Chris Takimoto也宣布将辞职。
Price Action: IGMS stock is down 13.20% at $14.36 at the last check on Tuesday.
价格走势：周二最后检查时，IGMS股价下跌13.20%，至14.36美元。
- Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients.
- Eli Lilly计划在非肥胖患者中为减肥药物进行新试验。
